AccScience Publishing / JBM / Online First / DOI: 10.14440/jbm.0234
Submit to JBM
Cite this article
4
Download
11
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
BRIEF REPORT

Comparative measurement of plasma soluble urokinase plasminogen activator receptor using a point-of-care device and a clinical analyzer in stroke patients

Areti Kourti1* ,  Eirini Keskilidou1 ,  Alexandra Skoura1 ,  Athanasia Samara1 ,  Paraskevi Thanou1 ,  Paraskevi Karalazou1 ,  Katerina Thisiadou1 ,  Kali Makedou1
Show Less
1 Laboratory of Biochemistry, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Central Macedonia 54124, Greece
JBM, e99010052 https://doi.org/10.14440/jbm.0234
Submitted: 1 August 2025 | Revised: 14 December 2025 | Accepted: 14 January 2026 | Published: 23 February 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Background: Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation and chronic inflammatory responses and has been proposed as a prognostic biomarker in several acute conditions. Objectives: This study aims to evaluate the clinical performance of two analytical methods for plasma suPAR determination in patients with stroke: a point-of-care (POC) lateral-flow assay and an automated particle-enriched turbidimetric immunoassay performed on a biochemistry analyzer. Methods: Plasma samples from 27 patients with stroke and 14 age-matched healthy controls were analyzed with both methods. suPAR concentrations were significantly higher in stroke patients compared with controls for both assays. Results: A statistically significant difference between POC and analyzer measurements was observed only within the stroke group (p=0.024), and a strong positive correlation between the two methods was identified (r = 0.745, p<0.001). Receiver operating characteristic analysis demonstrated higher sensitivity for the POC method (96%) compared with the analyzer (82%), while the specificity was identical (57%). Conclusion: These findings suggest that suPAR measurement using a rapid POC platform provides reliable results and may support early risk stratification in patients with stroke in emergency department settings.

Keywords
Soluble urokinase plasminogen activator receptor
Point-of-care
Biochemistry analyzer
Stroke
Funding
None.
Conflict of interest
The authors declare they have no competing interests.
References
  1. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: Degradation products or active molecules? Thromb Haemost. 2005;93(2):192-198. doi: 10.1160/th04-09-0580

 

  1. Thunø M, Macho B, Eugen-Olsen J. suPAR: The molecular crystal ball. Dis Markers. 2009;27(3):157-172. doi: 10.3233/dma-2009-0657

 

  1. Guthoff M, Wagner R, Randrianarisoa E, et al. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep. 2017;7:40627. doi: 10.1038/srep40627

 

  1. Goodchild TT, Li Z, Lefer DJ. Soluble urokinase plasminogen activator receptor: From biomarker to active participant in atherosclerosis and cardiovascular disease. J Clin Invest. 2022;132(24):e165868. doi: 10.1172/jci165868

 

  1. Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12:780641. doi: 10.3389/fimmu.2021.780641

 

  1. Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014;9(10):e110555. doi: 10.1371/journal.pone.0110555

 

  1. Bahrami HSZ, Jørgensen PG, Hove JD, et al. Soluble urokinase plasminogen activator receptor and interleukin-6 improves prediction of all-cause mortality and major adverse cardiovascular events in type 1 diabetes. J Intern Med. 2025;298(3):188-199. doi: 10.1111/joim.20108

 

  1. Śmiłowska K, Śmiłowski M, Partyka R, Kokocińska D, Jałowiecki P. Personalised approach to diagnosing and managing ischemic stroke with a plasma-soluble urokinase-type plasminogen activator receptor. J Pers Med. 2022;12(3):457. doi: 10.3390/jpm12030457

 

  1. Chandna A, Mahajan R, Gautam P, et al. Point-of-care prognostication in moderate COVID-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test. PLOS Glob Public Health. 2023;3(8):e0001538. doi: 10.1371/journal.pgph.0001538

 

  1. Sajanti A, Hellström S, Bennett C, et al. Soluble urokinase-type plasminogen activator receptor and inflammatory biomarker response with prognostic significance after acute neuronal injury - a prospective cohort study. Inflammation. 2025;48:2217-2229. doi: 10.1007/s10753-024-02185-1

 

  1. Schmidt TP, Albanna W, Weiss M, et al. The role of soluble urokinase plasminogen activator receptor (suPAR) in the context of aneurysmal subarachnoid hemorrhage (aSAH)-a prospective observational study. Front Neurol. 2022;13:841024. doi: 10.3389/fneur.2022.841024

 

  1. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American heart association/American stroke association stroke council; council on cardiovascular surgery and anesthesia; council on cardiovascular radiology and intervention; council on cardiovascular nursing; and the interdisciplinary council on peripheral vascular disease. The American academy of neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-2293. doi: 10.1161/strokeaha.108.192218

 

  1. World Health Organization. The Top 10 Causes of Death; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death [Last accessed on 2025 Jul 28].

 

  1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371(9624):1612-1623. doi: 10.1016/S0140-6736(08)60694-7

 

  1. Folyovich A, Biró E, Orbán C, et al. Relevance of novel inflammatory markers in stroke-induced immunosuppression. BMC Neurol. 2014;14:41. doi: 10.1186/1471-2377-14-41

 

  1. Różański D, Szlufik S, Tomasiuk R, et al. Soluble urokinase plasminogen activator receptor levels correlation with other inflammatory factors in prognosis of disability and death in patients with ischemic stroke. Brain Sci. 2021;12(1):39. doi: 10.3390/brainsci12010039

 

  1. Persson M, Östling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: A risk factor for carotid plaque, stroke, and coronary artery disease. Stroke. 2014;45(1): 18-23. doi: 10.1161/strokeaha.113.003305

 

  1. Wang B, Wang J, Qi C, et al. Soluble urokinase plasminogen activator receptor promotes endoplasmic reticulum stress and apoptosis susceptibility through RAGE in sepsis acute kidney injury. Mol Med. 2025;31(1):296. doi: 10.1186/s10020-025-01352-w
Next article in this issue
Share
Back to top
Journal of Biological Methods, Electronic ISSN: 2326-9901 Print ISSN: TBA, Published by POL Scientific
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept